First Time Loading...

Abbvie Inc
NYSE:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist
Price: 166.41 USD 1.06% Market Closed
Updated: Apr 20, 2024
Section:
 

Wall Street
Price Targets

ABBV Price Targets Summary
Abbvie Inc

Wall Street analysts forecast ABBV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABBV is 188.18 USD with a low forecast of 162.61 USD and a high forecast of 217.35 USD.

ABBV Lowest Forecast
Wall Street Target
162.61 USD
2% Downside
ABBV Average Forecast
Wall Street Target
188.18 USD
13% Upside
ABBV Highest Forecast
Wall Street Target
217.35 USD
31% Upside
Lowest
Price Target
162.61 USD
2% Downside
Average
Price Target
188.18 USD
13% Upside
Highest
Price Target
217.35 USD
31% Upside

ABBV Last Price Targets
Abbvie Inc

The latest public price target was made on Mar 27, 2024 by Carter Gould from Barclays , who expects ABBV stock to rise by 17% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Carter Gould
Barclays
195 USD
Upside 17%
3 weeks ago
Mar 27, 2024
Abbvie (ABBV) PT Raised to $195 at Barclays
StreetInsider
Christopher Raymond
Raymond James
170 USD
Upside 2%
5 months ago
Nov 9, 2023
Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts
Benzinga
Gary Nachman
Raymond James
177 USD
Upside 6%
6 months ago
Sep 29, 2023
AbbVie's Promising Leap Towards Long-Term Growth: Analyst
Benzinga
Vamil Divan
Guggenheim
171 USD
Upside 3%
11 months ago
May 9, 2023
Check Out 3 Health Care Stocks With Over 3% Dividend Yields From Wall Street's Most Accurate Analysts
Benzinga
Unknown Analyst
BMO Capital
167 USD
Upside 0%
1 year ago
Feb 6, 2023
BMO Capital Maintains Outperform on AbbVie, Lowers Price Target to $167
Benzinga
Carter Gould
Barclays
Price Target 195 USD
Upside/Downside 17%
View Source
Christopher Raymond
Raymond James
Price Target 170 USD
Upside/Downside 2%
View Source
Gary Nachman
Raymond James
Price Target 177 USD
Upside/Downside 6%
View Source
Vamil Divan
Guggenheim
Price Target 171 USD
Upside/Downside 3%
View Source
Unknown Analyst
BMO Capital
Price Target 167 USD
Upside/Downside 0%
View Source
Abbvie Inc Competitors:
Price Targets
Y
301301
Yili Chuanning Biotechnology Co Ltd
13% Upside
IMGN
ImmunoGen Inc
18% Downside
HOOK
HOOKIPA Pharma Inc
554% Upside
E
206650
EuBiologics Co Ltd
20% Upside
Y
301301
Yili Chuanning Biotechnology Co Ltd
13% Upside
IMGN
ImmunoGen Inc
18% Downside
HOOK
HOOKIPA Pharma Inc
554% Upside
E
206650
EuBiologics Co Ltd
20% Upside
IMTX
Immatics NV
87% Upside
1672
Ascletis Pharma Inc
137% Upside
SPRO
Spero Therapeutics Inc
446% Upside
688520
Sinocelltech Group Ltd
86% Upside

Revenue
Forecast

Revenue Estimate
Abbvie Inc

For the last 8 years the compound annual growth rate for Abbvie Inc's revenue is 11%. The projected CAGR for the next 3 years is 5%.

11%
Past Growth
5%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Abbvie Inc

For the last 8 years the compound annual growth rate for Abbvie Inc's operating income is 10%. The projected CAGR for the next 3 years is 21%.

10%
Past Growth
21%
Estimated Growth
Estimates Accuracy
-20%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Abbvie Inc

For the last 8 years the compound annual growth rate for Abbvie Inc's net income is -1%. The projected CAGR for the next 3 years is 72%.

-1%
Past Growth
72%
Estimated Growth
Estimates Accuracy
-51%
Average Miss
What are analyst estimates?

See Also

Summary
ABBV intrinsic value, competitors valuation, and company profile.
DCF Valuation
ABBV stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ABBV stock valuation using valuation multiples.
Wall Street Estimates
ABBV price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ABBV stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ABBV's stock price target?
Price Target
188.18 USD

According to Wall Street analysts, the average 1-year price target for ABBV is 188.18 USD with a low forecast of 162.61 USD and a high forecast of 217.35 USD.

What is Abbvie Inc's Revenue forecast?
Projected CAGR
5%

For the last 8 years the compound annual growth rate for Abbvie Inc's revenue is 11%. The projected CAGR for the next 3 years is 5%.

What is Abbvie Inc's Operating Income forecast?
Projected CAGR
21%

For the last 8 years the compound annual growth rate for Abbvie Inc's operating income is 10%. The projected CAGR for the next 3 years is 21%.

What is Abbvie Inc's Net Income forecast?
Projected CAGR
72%

For the last 8 years the compound annual growth rate for Abbvie Inc's net income is -1%. The projected CAGR for the next 3 years is 72%.

ALPHA SPREAD
Join more than 129,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.